Pelthos Therapeutics Inc.: director Peter Greenleaf sold 797 shares

What happened

• Peter Greenleaf, a director, sold 797 shares at $21.17 per share in an open-market sale on Oct 2, 2026, for $16,872.
• The filing notes the sale was made pursuant to a Rule 10b5-1 plan adopted Dec 16, 2025, to satisfy estimated tax obligations in connection with the vesting of restricted stock units.

Key details

• Transaction date and price: Oct 2, 2026 — sale of 797 shares at $21.17 each, total $16,872.
• Shares owned after the transaction: the filing does not report shares owned following the transaction.
• Footnote: sale pursuant to a Rule 10b5-1 plan adopted Dec 16, 2025, to satisfy estimated tax obligations related to RSU vesting (footnote F1).
• Filing date and accession: Form 4 filed Oct 6, 2026 (accession 0001919246-26-000131); the filing does not indicate whether it was late.

Why it may matter

• The filing shows this was a market sale executed under a pre-established Rule 10b5-1 plan for tax withholding tied to restricted stock unit vesting.
• A filing does not show why the insider traded or why the company acted.